Generated total revenues of $110.4 million in the third quarter, including $75.3 million for SYFOVRE® and $23.9 million for EMPAVELI® SYFOVRE showed continued strong demand with growth.
Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Generated U.S. net product revenues of $18.4 million for SYFOVRE™ and $20.4 million for EMPAVELI® SYFOVRE launched in the U.S. as the first and only treatment for geographic atrophy . | May 4, 2023
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Stock Market | FinancialContent Business Page financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.